FAS and plasma cell myeloma: In multiple myeloma cells, edelfosine demonstrated great ability to induce modifications in membrane-lipid raft structure clustering Fas/CD95 death receptors and lipid rafts [26,70,71,72]; however, its clinical application has been limited due to gastrointestinal toxicity, hemolytic potential, and metabolic instability [5].